CN107223961A - 一种具有解酒保肝作用的组合物及其制备方法 - Google Patents
一种具有解酒保肝作用的组合物及其制备方法 Download PDFInfo
- Publication number
- CN107223961A CN107223961A CN201610175040.9A CN201610175040A CN107223961A CN 107223961 A CN107223961 A CN 107223961A CN 201610175040 A CN201610175040 A CN 201610175040A CN 107223961 A CN107223961 A CN 107223961A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- extract
- composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000000694 effects Effects 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 210000004185 liver Anatomy 0.000 title claims abstract description 17
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 13
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 13
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 51
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 51
- 210000000582 semen Anatomy 0.000 claims abstract description 44
- 244000185386 Thladiantha grosvenorii Species 0.000 claims abstract description 31
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 230000002829 reductive effect Effects 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 23
- 239000004376 Sucralose Substances 0.000 claims description 17
- 235000019408 sucralose Nutrition 0.000 claims description 17
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 17
- 235000020985 whole grains Nutrition 0.000 claims description 17
- 229920002472 Starch Polymers 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- 239000008107 starch Substances 0.000 claims description 16
- 235000019698 starch Nutrition 0.000 claims description 16
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 15
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 15
- 239000000811 xylitol Substances 0.000 claims description 15
- 235000010447 xylitol Nutrition 0.000 claims description 15
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 15
- 229960002675 xylitol Drugs 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 13
- 239000005913 Maltodextrin Substances 0.000 claims description 12
- 229920002774 Maltodextrin Polymers 0.000 claims description 12
- 229940035034 maltodextrin Drugs 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 229940032147 starch Drugs 0.000 claims description 9
- 108010011485 Aspartame Proteins 0.000 claims description 7
- 239000000605 aspartame Substances 0.000 claims description 7
- 235000010357 aspartame Nutrition 0.000 claims description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 7
- 229960003438 aspartame Drugs 0.000 claims description 7
- 235000009508 confectionery Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 244000202052 Poncirus trifoliata Species 0.000 claims description 2
- 235000000404 Poncirus trifoliata Nutrition 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 229960001367 tartaric acid Drugs 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 1
- 230000035622 drinking Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 239000012530 fluid Substances 0.000 abstract description 3
- 206010019233 Headaches Diseases 0.000 abstract description 2
- 230000002075 anti-alcohol Effects 0.000 abstract description 2
- 231100000869 headache Toxicity 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 210000005229 liver cell Anatomy 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000003826 tablet Substances 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 240000006394 Sorghum bicolor Species 0.000 description 4
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010003084 Areflexia Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 229940100445 wheat starch Drugs 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007171 Imperata cylindrica Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有解酒保肝作用的组合物及其制备方法,该组合物主要是由枳椇子、葛根、白茅根、甘草、罗汉果按一定重量配比制备而成。它可以被制备成任何一种常用剂型,优选口服制剂。该组合物由药食同源的中药制成,具有解酒保肝、清热生津、理气健脾、缓解酒后肝火旺盛、头痛的作用,特别适合酒后服用。
Description
技术领域
本发明涉及一种具有解酒保肝作用的组合物及其制备方法,属于食品或保健食品的技术领域。
背景技术
在人们的日常生活和社会交往中,常常有饮酒过量的情况,醉酒后人们往往有神智不清、头痛、反胃等症状,严重者还会酒精中毒。长期饮酒不可避免地对肝脏造成伤害,过量饮酒对人体的损害已引起人们的高度重视。本发明提供了一种具有解酒保肝作用的利用药食同源中药制成的食品,解决了这一问题,促进了人们的身体健康。
发明内容
本发明主要解决的技术问题是提供一种具有解酒保肝作用的组合物;本发明还提供了该组合物的制备方法。
本发明是通过以下技术方案实现的:
本发明是由下述重量份的组分制成的:
枳椇子30-90份、葛根70-130份、白茅根30-90份、甘草5-60份。
优选为:
枳椇子40-80份、葛根80-120份、白茅根40-80份、甘草10-50份。
进一步优选为:
枳椇子50-70份、葛根90-110份、白茅根50-70份、甘草20-40份。
本发明组合物中还可以包括有罗汉果10-70份,优选20-60份,进一步优选30-50份。
本发明组合物最佳优选为:
枳椇子60份、葛根100份、白茅根60份、甘草30份、罗汉果40份。
本发明涉及一种组合物,它是在现有中医理论的基础上,进行科学配伍,发挥组分之间相互协同的作用,从而筛选出能解酒保肝的组方。其中,枳椇子,又名拐枣,为鼠李科拐枣属植物,药用部分为带有肉质果柄的果实或种子,成熟时红褐色,光滑无毛,甜香可口。果实圆球形,内含三粒红褐色种子。它既是名果之一,也是一种稀罕的药用食用果品。该植物始载于《唐本草》果部,李时珍称它为金果树,并在《本草纲目》第31 卷中有记载。此外《雷公炮炙论》《救荒本草》等多部医药著作中均有收载。该物属养阴、生津、润燥、止渴、凉血类药物,中医认为其有清热利尿,解酒毒之功效,主治酒毒、烦热、口渴、呕吐、二便不利等症。枳椇子主要含生物碱类、黄酮类、脂肪酸类、皂苷类、糖苷类、葡萄糖、苹果酸、没食子儿茶素等化合物。枳椇子药理作用有:缩短小鼠醒酒时间;加快乙醇代谢;显著提高血中谷胱甘肽过氧化物酶(GSH-px) 活力;显著降低乙醇所致肝脏过氧化脂质含量升高;乙醇诱导的肌松作用有抑制作用;对乙醇所致肝损伤的预防作用;对CCl4 诱导的体外培养肝细胞损伤具保护作用。
葛根具有解肌发表,辛凉透疹,退热生津,止渴止泻,升举阳气之功效。其有解酒作用的记载至少有二千五百年,唐朝《食疗本草》中指出:“葛根蒸食之,消酒毒。”《千金方》、《药性论》也记载葛根“解酒毒”、“治酒醉不醒”;《中药大辞典》载:葛根,具清热解毒,解痉镇痛,升阳解肌,透疹止泻,增加脑和冠状血流,改善脑微循环等作用。王庆端等的实验表明葛根中的总黄酮成分可以提高小鼠对乙醇的耐受量,缩短小鼠大剂量乙醇中毒时翻正反射消失的时间,并缩短睡眠潜伏期,降低血中乙醇含量。药理研究表明葛根具有较强的解酒作用,能有效拮抗酒精引起的肝和睾丸组织脂质过氧化损害;葛根含大豆甙,它能分解乙醛毒性,阻止酒精对大脑抑制功能的减弱,抑制肠胃对酒精的吸收,促进血液中酒精的代谢和排泄。此外葛根还具有抗氧化,免疫功能增强的作用,并能够降血糖、血脂,改善血液循环,具有较强的增强心脑血管功能的作用。病理学研究资料表明服用葛根水提液可以降低乙醇所致的肝细胞产生脂肪变性。
白茅根具有清热生津,凉血止血,利尿的功效。因其味甘性寒,善清肺、胃之热,因它有利水作用,故能导热下行。它的特点是:味甘而不泥膈,性寒而不碍胃,利水而不伤阴,尤以热症而有阴津不足现象者,最为适用。《本草纲目》云:“白茅根,甘能除伏热,利小便,故能止诸血、哕逆、喘急、消渴,治黄疸水肿,乃良物也。……止吐衄诸血,伤寒哕逆,肺热喘急,水肿,黄疸,解酒毒。”药理研究表明,白茅根煎剂和水浸剂灌服,对正常家兔有利尿作用,并认为白茅根的利尿作用与其所含的丰富钾盐有关。
甘草补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。陶弘景将甘草尊为“国老”,并言:“此草最为众药之王,经方少有不用者。”“国老”,即帝师之称。《本草纲目》中所释:“诸药中甘草为君,治七十二种乳石毒,解一千二百草木毒,调和众药有功,故有‘国老’之号。”
罗汉果:甘、酸、性凉。营养价值高,有清热解暑、化痰止咳、凉血舒骨、清肺润肠、生津止渴等功效,可治急慢性气管炎、咽喉炎、支气管哮喘、百日咳、胃热、便秘、急性扁桃体炎等症。现代医学证明,罗汉果对支气管炎、高血压等疾病有显著疗效,还可以起到防治冠心病、血管硬化、肥胖症的作用。
本发明组合物的制备方法如下:
将所述重量份的原料药直接粉碎得到粉末;或加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用水提醇沉法、有机溶剂萃取法、柱层析法、二氧化碳超临界萃取法、水蒸气蒸馏法进行精制得到精提物;上述粉末或粗提物或精提物不加或者加入适量辅料,按常规工艺制备而成。
如可以制成常用的片剂(分散片、泡腾片、口腔崩解片、含片、咀嚼片、泡腾片)、胶囊剂(硬胶囊、软胶囊)、颗粒剂、丸剂(滴丸剂)、散剂等固体制剂形式,也可以制成糖浆、酒剂、酊剂、口服液等液体制剂形式。因此,该组合物中除有效成分外,还可以含有药学上可以接受的辅料。
这里所述的辅料,可以根据不同的制剂有所不同,如在片剂、胶囊剂、颗粒剂等固体制剂中常用的稀释剂、崩解剂、赋形剂、粘合剂、润滑剂、表面活性剂、填充剂、矫味剂等;在糖浆、口服液等液体制剂形式中常用的表面活性剂、稀释剂、防腐剂、稳定剂、矫味剂、增稠剂、助流剂等。
其常用辅料如淀粉、乳糖、蔗糖、三氯蔗糖、糊精、麦芽糊精、糖粉、微晶纤维素、甘露醇、木糖醇、聚乙二醇、硫酸钙、磷酸氢钙、碳酸钙、改良淀粉、山梨醇、聚乙烯吡咯烷酮、重质碳酸镁、羧甲基纤维素钠、羟丙甲基纤维素、甲基纤维素、乙基纤维素、羧甲淀粉钠、羟丙基纤维素、聚维酮K30、白陶土、预胶化淀粉、硬脂酸镁、滑石粉、微粉硅胶、甜叶菊苷、甜菜碱、阿司帕坦、甘草甜素、糖精钠、柠檬酸、酒石酸、冰糖、蜂蜜、牛奶香精等。
本发明组合物优先被制成颗粒剂,制备方法如下:
将所述重量份的原料药加水提取,过滤,合并滤液,减压浓缩至稠膏,加入适量辅料,混匀,制粒,干燥,即得。
优选的制备方法如下:
将所述重量份的原料药加6-12倍量水提取1-3次,每次1-3小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量填充剂,混匀,制粒,干燥,整粒,加入适量矫味剂,混匀,即得。
其中,所述的填充剂是指糊精、淀粉、甘露醇、麦芽糊精、木糖醇、乳糖、微晶纤维素中的一种或一种以上,优选淀粉、麦芽糊精、木糖醇;矫味剂是指蔗糖、三氯蔗糖、柠檬酸、酒石酸、阿司帕坦、甜菜碱、乳糖中的一种或一种以上,优选柠檬酸、三氯蔗糖。
本发明组合物颗粒剂的具体制备方法如下:
将所述重量份的原料药加8倍量水提取2次,每次1.5小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
本发明组合物颗粒剂的制备方法还可以为:
将所述重量份的原料药加6-12倍量50-90%乙醇提取1-3次,每次1-3小时,过滤,合并滤液,减压回收乙醇至无醇味,继续浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
本发明组合物片剂的具体制备方法如下:
将所述重量份的原料药加8倍量水提取2次,每次1.5小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,加入适量硬脂酸镁,混匀,压片,包衣或不包衣,即得。
本发明组合物袋泡茶的制备方法如下:
将所述重量份的原料药直接粉碎得到粉末,混匀,包装,即得。
以下通过实施例形式的具体实施方式,对本发明的上述内容作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实施例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
实施例1
枳椇子600g、葛根1000g、白茅根600g、甘草300g、罗汉果400g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加8倍量水提取2次,每次1.5小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
实施例2
枳椇子500g、葛根1100g、白茅根500g、甘草400g、罗汉果300g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加8倍量水提取2次,每次1.5小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
实施例3
枳椇子700g、葛根900g、白茅根700g、甘草200g,罗汉果500g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加8倍量水提取2次,每次1.5小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
实施例4
枳椇子300g、葛根1300g、白茅根300g、甘草600g、罗汉果100g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加12倍量水提取1次,提取3小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、糊精、甘露醇,混匀,制粒,干燥,整粒,加入适量蔗糖、酒石酸,混匀,即得。
实施例5
枳椇子900g、葛根700g、白茅根900g、甘草50g、罗汉果700g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加6倍量水提取3次,每次1小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精,混匀,制粒,干燥,整粒,加入适量阿司帕坦,混匀,即得。
实施例6
枳椇子400g、葛根1200g、白茅根400g、甘草500g、罗汉果200g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加10倍量水提取2次,每次2小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量糊精、淀粉、乳糖,混匀,制粒,干燥,整粒,加入适量阿司帕坦、甜菜碱,混匀,即得。
实施例7
枳椇子800g、葛根800g、白茅根800g、甘草100g、罗汉果600g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加8倍量水提取2次,每次2小时,过滤,合并滤液,减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
实施例8
枳椇子600g、葛根1000g、白茅根600g、甘草300g
将所述重量份的枳椇子、葛根、白茅根、甘草加8倍量水提取2次,每次1.5小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
实施例9
枳椇子650g、葛根950g、白茅根650g、甘草250g、罗汉果450g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加8倍量水提取2次,每次2小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量乳糖,混匀,制粒,干燥,整粒,装胶囊,即得。
实施例10
枳椇子550g、葛根1050g、白茅根550g、甘草350g、罗汉果350g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加8倍量70%乙醇提取2次,每次2小时,过滤,合并滤液,减压回收乙醇至无醇味,继续浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
实施例11
枳椇子700g、葛根900g、白茅根700g、甘草400g、罗汉果300g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加10倍量水提取2次,每次2小时,过滤,合并滤液,减压浓缩至稠膏,加入适量糊精、微晶纤维素、甘露醇,混匀,制粒,干燥,加入适量硬脂酸镁,混匀,压片,包衣,即得片剂。
实施例12
枳椇子500g、葛根1100g、白茅根500g、甘草200g、罗汉果500g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果加10倍量水提取2次,每次2小时,过滤,合并滤液,减压浓缩至稠膏,加入适量三氯蔗糖、阿司帕坦,混匀,加水至全量,即得口服液体制剂。
实施例13
枳椇子1000g、葛根1000g、白茅根600g、甘草300g、罗汉果400g
将所述重量份的枳椇子、葛根、白茅根、甘草、罗汉果直接粉碎成粉末,混匀,包装,即得袋装茶剂。
实施例14
枳椇子550g、葛根1050g、白茅根550g、甘草350g
将所述重量份的枳椇子、葛根、白茅根、甘草加8倍量70%乙醇提取2次,每次2小时,过滤,合并滤液,减压回收乙醇至无醇味,继续浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
实施例15
枳椇子600g、葛根1000g、白茅根600g、甘草300g
将所述重量份的枳椇子、葛根、白茅根、甘草加8倍量水提取2次,每次1.5小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
实施例16
枳椇子700g、葛根900g、白茅根700g、甘草400g
将所述重量份的枳椇子、葛根、白茅根、甘草加10倍量水提取2次,每次2小时,过滤,合并滤液,减压浓缩至稠膏,加入适量糊精、微晶纤维素、甘露醇,混匀,制粒,干燥,加入适量硬脂酸镁,混匀,压片,包衣,即得片剂。
实施例17
枳椇子500g、葛根1100g、白茅根500g、甘草200g
将所述重量份的枳椇子、葛根、白茅根、甘草加10倍量水提取2次,每次2小时,过滤,合并滤液,减压浓缩至稠膏,加入适量三氯蔗糖、阿司帕坦,混匀,加水至全量,即得口服液体制剂。
实施例18
枳椇子1000g、葛根1000g、白茅根600g、甘草300g
将所述重量份的枳椇子、葛根、白茅根、甘草直接粉碎成粉末,混匀,包装,即得袋装茶剂。
以上均为本发明较佳的实现方案,除此之外,本发明还可以其他实现方式,需要说明的是,在没有脱离本发明发明构思的前提下,任何显而易见的替换均在本发明保护范围之内。
以下通过试验例来进一步阐述本发明所述组合物的有益效果。
试验例一:本发明组合物对小鼠解酒能力的影响
1、材料:
本发明组合物:按照本发明实施例1制得的样品;
56°红星二锅头,北京红星二锅头酒厂生产;
动物昆明种小鼠,体重20~22g,雌雄各半。
2、方法和结果:
取昆明种小鼠20只,雌雄兼用,在实验室饲养1d。然后禁食5h,称重标记后随机分为模型组(空白对照组)、本发明组合物组,每组10只。先灌胃给酒,给酒剂量0.25ml/20g,给酒后立即给药,空白对照组给予蒸馏水。以翻正反射消失为睡眠指标,计算耐受时间(从乙醇灌胃到翻正反射消失的时间)及醉睡时间(从翻正反射消失到恢复的时间)。对2组数据进行单因素方差分析处理,结果见表1、表2。
表1 本发明组合物对小鼠醉睡耐受时间的影响(x±S)
组别 | 动物数/只 | 未醉/只 | 醉睡/只 | 耐受时间/min |
模型(空白对照) | 10 | 0 | 10 | 2.5±1.2 |
本发明组合物 | 10 | 7 | 3 | 25.4±16.3** |
与模型组比较,**P<0.01
表2 本发明组合物对小鼠醉睡维持时间的影响(x±S)
组别 | 动物数/只 | 未醉/只 | 醉睡/只 | 耐受时间/min |
模型(空白对照) | 10 | 0 | 10 | 162.17±30.4 |
本发明组合物 | 10 | 7 | 3 | 27.6±14.1** |
与模型组比较,**P<0.01
本发明实施例2-18均按照上述方法进行了相似的试验,结果与上述结果相同。
结论:本发明组合物可明显增强小鼠的耐受时间(P<0.01),缩短小鼠的睡眠时间(P<0.01),具有明显的统计学意义和量效关系。提示本发明组合物具有明显的解酒作用。
试验例二:本发明组合物对小鼠的保肝作用
1、材料
本发明组合物:按照本发明实施例1制得的样品;
56°红星二锅头,北京红星二锅头酒厂生产;
动物昆明种小鼠,体重20~22g,雌雄各半。
2、方法
2.1 分组给药:将动物随机分为3组,每组10只。各组均以小鼠标准饲料喂养,自由饮水,喂养3d后进入实验。模型组灌胃给酒0.3ml/只/d,30min后给水0.3ml/只;本发明组合物组给酒量同模型组,30min后给本发明组合物浓缩液灌胃0.3ml/只;正常对照组灌胃给水,量和时间同上两组。各组喂养环境相同,实验周期为45d。
2.2 观察指标及检测方法:
2.2.1体重、活动状况及对外来刺激的反应、存活率
2.2.2酒精浓度:在45d后从内眦取血,灌胃给酒后30min取血样。检测方法为: 取0.1ml血稀释到5ml,取0.1ml进样,用气象色谱检测血中酒精的浓度。
2.2.3肝脏组织结构变化:45d后处死,取出动物肝脏,立即用10%甲醛溶液固定,常规石蜡包埋,切片6mm,普通HE染色,光镜下观察组织结构的变化
3、结果
3.1 各组体重、存活率、活动状况及对外来刺激的变化:实验开始时,各组体重无明显差别,20d后模型组身体倦怠,本发明组合物组变化轻微。45d后模型组、本发明组合物组较正常对照组体重明显减轻,模型组较本发明组合物明显变轻。每日给酒后,模型组在10min内出现行走不稳,平衡能力下降,不能爬笼,四肢外伸,呼吸变浅,反应迟钝,倦卧少动,精神萎靡。本发明组合物组上述症状20min后出现,且症状较微,精神、活动较好,对外界刺激有明显反应,并能爬笼登高。
3.2 45d测血酒精浓度,模型组明显高于本发明组合物组(P<0.01),结果见表3。
表3 各组鼠存活率、体重变化、血液酒精浓度(x±S)
组别 | 动物数/只 | 存活率 | 45d体重/g | 酒精浓度 |
正常对照组 | 10 | 100% | 31.2±0.8 | 1.16±0.3 |
模型组 | 10 | 60% | 22.6±0.5 | 135.4±10.9 |
本发明组合物 | 10 | 80% | 28.4±0.6* | 72.1±8.2** |
与模型组比较:*P<0.01;与模型组比较:**P<0.01
3.3 光镜下观察肝脏组织结构变化:正常对照组以中央静脉(填充有RBC)为中心的肝细胞板基本可见,肝细胞稍有抽脱现象,汇管可见肝小叶分界不明显(肝小叶结缔组织极少),叶间静脉扩张,填充有RBC;模型组部分小叶下静脉周围的肝细胞板肝细胞变性、坏死,核固缩(深染),核碎裂,部分小叶下静脉遭到破坏,肝细胞有较多小脂滴出现,变性肝细胞中有凋亡小体出现;本发明组合物组基本与正常对照组相同,可见少部分区域成陈旧性坏死,区域内有正常肝细胞恢复增生,无新生坏死区域。
本发明实施例2-18均按照上述方法进行了相似的试验,结果与上述结果相同。
结论:通过实验表明,本发明组合物对酒精中毒小鼠肝脏具有保护作用,维护了肝细胞的正常结构和代谢功能,增加了酒精的代谢速率,降低了血液中的酒精浓度,同时改善了机体的应激状态,特别是中枢神经系统的适应性,使酒精对中枢神经系统的抑制或兴奋作用减轻。
Claims (10)
1.一种具有解酒保肝作用的组合物,其特征在于,它是由下述重量配比的原料制成的:枳椇子30-90份、葛根70-130份、白茅根30-90份、甘草5-60份。
2.根据权利要求1所述的组合物,其特征在于,它是由下述重量配比的原料制成的:枳椇子50-70份、葛根90-110份、白茅根50-70份、甘草20-40份。
3.根据权利要求1所述的组合物,其特征在于,它还包括罗汉果10-70份。
4.根据权利要求2所述的组合物,其特征在于,它还包括罗汉果30-50份。
5.权利要求1或2或3或4所述组合物的制备方法,其特征在于,它是这样制备的:
将所述重量份的原料药直接粉碎得到粉末;或加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用水提醇沉法、有机溶剂萃取法、柱层析法、二氧化碳超临界萃取法、水蒸气蒸馏法进行精制得到精提物;上述粉末或粗提物或精提物不加或者加入适量辅料,按常规工艺制备而成。
6.根据权利要求5所述的制备方法,其特征在于,它是这样制备的:
将所述重量份的原料药加水提取,过滤,合并滤液,减压浓缩至稠膏,加入适量辅料,混匀,制粒,干燥,即得。
7.根据权利要求6所述的制备方法,其特征在于,它是这样制备的:
将所述重量份的原料药加6-12倍量水提取1-3次,每次1-3小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量填充剂,混匀,制粒,干燥,整粒,加入适量矫味剂,混匀,即得。
8.根据权利要求7所述的制备方法,其特征在于,所述的填充剂是指糊精、淀粉、甘露醇、麦芽糊精、木糖醇、乳糖、微晶纤维素中的一种或一种以上;矫味剂是指蔗糖、三氯蔗糖、柠檬酸、酒石酸、阿司帕坦、甜菜碱中的一种或一种以上。
9.根据权利要求5或6所述的制备方法,其特征在于,它是这样制备的:
将所述重量份的原料药加8倍量水提取2次,每次1.5小时,过滤,合并滤液,适当浓缩后离心,取上清液减压浓缩至稠膏,干燥,粉碎,加入适量淀粉、麦芽糊精、木糖醇,混匀,制粒,干燥,整粒,加入适量柠檬酸、三氯蔗糖,混匀,即得。
10.权利要求1或2或3或4所述组合物用于制备具有解酒保肝作用的食品或保健食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610175040.9A CN107223961A (zh) | 2016-03-25 | 2016-03-25 | 一种具有解酒保肝作用的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610175040.9A CN107223961A (zh) | 2016-03-25 | 2016-03-25 | 一种具有解酒保肝作用的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107223961A true CN107223961A (zh) | 2017-10-03 |
Family
ID=59931940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610175040.9A Pending CN107223961A (zh) | 2016-03-25 | 2016-03-25 | 一种具有解酒保肝作用的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107223961A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107669930A (zh) * | 2017-11-01 | 2018-02-09 | 武汉草根生物医药科技有限公司 | 一种用于治疗痛风的压片及其制备方法 |
CN108578518A (zh) * | 2018-05-28 | 2018-09-28 | 陕西科技大学 | 一种用于醉酒人群的口腔崩解片及其制备方法 |
CN111096386A (zh) * | 2020-01-18 | 2020-05-05 | 四川健腾生物技术有限公司 | 一种功能性压片糖果及其制备方法 |
-
2016
- 2016-03-25 CN CN201610175040.9A patent/CN107223961A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107669930A (zh) * | 2017-11-01 | 2018-02-09 | 武汉草根生物医药科技有限公司 | 一种用于治疗痛风的压片及其制备方法 |
CN108578518A (zh) * | 2018-05-28 | 2018-09-28 | 陕西科技大学 | 一种用于醉酒人群的口腔崩解片及其制备方法 |
CN111096386A (zh) * | 2020-01-18 | 2020-05-05 | 四川健腾生物技术有限公司 | 一种功能性压片糖果及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9968644B2 (en) | Traditional chinese medicine composition for sober-up and hepatic protection and a process for preparing the same | |
KR100574097B1 (ko) | 숙취해소 및 간기능 개선용 식품 조성물 | |
US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
CN107616501A (zh) | 一种具有清肺功能的组合物及其制备方法 | |
CN108201138A (zh) | 一种解酒护肝组合物、组合物的制剂及其制备方法 | |
CN103203008A (zh) | 用于解酒的药物组合物及其制备方法 | |
CN107617061A (zh) | 一种具有清肺润肺功能的组合物及其制备方法 | |
CN102960809A (zh) | 一种解酒饮料 | |
CN106031418A (zh) | 一种具有缓解体力疲劳功能的组合物及其制备方法 | |
CN103356807A (zh) | 一种具有增强免疫力功能的组合物及其制备方法 | |
CN108498597A (zh) | 一种解酒组合物 | |
KR101930277B1 (ko) | 숙취 예방 및 개선용 조성물 | |
CN107950929A (zh) | 一种具有改善睡眠功能的组合物及其制备方法和用途 | |
CN107223961A (zh) | 一种具有解酒保肝作用的组合物及其制备方法 | |
CN111375049B (zh) | 一种解酒保肝的组合物及其制备方法和应用 | |
CN106177746A (zh) | 一种对化学性肝损伤具有辅助保护作用的组合物及其制备方法 | |
CN101745087A (zh) | 一种具有解酒防醉作用的组合物及其制备方法 | |
CN107412665B (zh) | 一种具有解酒、防治酒精性肝损伤的中药组合物及其制备方法和应用 | |
CN105878812A (zh) | 以金花茶-石斛为原料的解酒饮料及其生产方法 | |
CN106822622A (zh) | 一种解酒护肝口服组合物及其制备方法 | |
CN103006922A (zh) | 一种具有解酒护肝功能的组合物 | |
KR20040041865A (ko) | 감기치료용 생약 조성물 | |
KR100392876B1 (ko) | 숙취제거용 음료 및 그의 제조 방법 | |
CN111567797A (zh) | 复方茉莉花茶咀嚼片及其制备方法 | |
CN110973625A (zh) | 基于火麻仁的护肝醒酒组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171003 |
|
WD01 | Invention patent application deemed withdrawn after publication |